Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Mingxue Fan, Minghao Li, Lipeng Gao, Sicong Geng, Jing Wang, Yiting Wang, Zhiqiang Yan, Lei Yu

Research output: Contribution to journalReview articlepeer-review

86 Scopus citations

Abstract

Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.

Original languageEnglish
Article number151
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
StatePublished - 29 Aug 2017

Keywords

  • Acute myeloid leukemia
  • Chimeric antigen receptors
  • Immunotherapy

Fingerprint

Dive into the research topics of 'Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this